Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123189) titled 'Efficacy and Safety of IOLF Regimen Combined with Bevacizumab and Serplulimab as Neoadjuvant Chemotherapy for Colorectal Cancer' on April 22.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Huashan Hospital, Fudan University
Condition:
Colorectal cancer
Intervention:
Experimental Group:IOLF regimen (Irinotecan + Oxaliplatin + 5-Fluorouracil)
Serplulimab
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-04-22
Target Sample Size: Experimental Group:28;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=3...